BriaCell - Update on Breast Cancer ๐๏ธ
-Shares of BriaCell Therapeutics Corp. BCTX, 111.64% more than doubled Wednesday on heavy volume, after the biotechnology company provided upbeat update on its breast cancer treatment.
-The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of "eye-bulging" tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials.
-
-The company the average overall survival benefit was 12.0 months, with a top-responder survival of 21.4 months plus 100% resolution of "eye-bulging" tumor, which compares with average 7.2 months to 9.8 months survival in historical comparison treatment trials.
-
๋ฉด์ฑ ์ฌํญ
์ด ์ ๋ณด์ ๊ฒ์๋ฌผ์ TradingView์์ ์ ๊ณตํ๊ฑฐ๋ ๋ณด์ฆํ๋ ๊ธ์ต, ํฌ์, ๊ฑฐ๋ ๋๋ ๊ธฐํ ์ ํ์ ์กฐ์ธ์ด๋ ๊ถ๊ณ ์ฌํญ์ ์๋ฏธํ๊ฑฐ๋ ๊ตฌ์ฑํ์ง ์์ต๋๋ค. ์์ธํ ๋ด์ฉ์ ์ด์ฉ ์ฝ๊ด์ ์ฐธ๊ณ ํ์ธ์.